Terns Pharmaceuticals, Inc. TERN 深 滬
已收盤 05-05 16:00:00 美东时间
52.95
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 52.95
- 總市值 61.17亿
- 52周最高 53.19
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 2.82
- 委 比 0.00%
- 總股本 1.16亿
- 歷史最高 53.19
- 量 比 0
- 振 幅 0.00%
- 歷史最低 1.45
- 每 手 1
- 風險率 18.58%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Oppenheimer Downgrades Terns Pharmaceuticals to Perform, Removes Price Target $58
Oppenheimer analyst Jay Olson downgrades Terns Pharmaceuticals (NASDAQ:TERN) from Outperform to Perform and removes the price target of $58.
04-27 22:00
Merck's Waiting Period Expires Under Hart-Scott-Rodino Antitrust Improvements Act To Acquire Terns Pharmaceuticals
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), in connection with
04-24 19:35
Large Drugmakers Eye Inhibrx Cancer Drugs Valued Over $8 Billion, Stock Surges
Inhibrx explores spin-off of INBRX-106 amid Big Pharma interest, with potential valuation exceeding $9 billion pending trial outcomes.
04-23 02:20
美股大行评级 | 小摩上调Bloom Energy目标价从166美元升至231美元；目标价28美元！大摩、高盛等多家机构首予Janus Living(JAN)超配评级
今日重点评级关注：Ascendiant Capital：维持Banzai International"买入"评级，目标价从23美元升至24美元；Ascendiant Capital：维持Synergy CHC Corp."买入"评级，目标价从5美元升至5.5美元
04-15 11:31
Merck Lowered Terns Pharmaceuticals Offer Price After Trial Data Review
Merck cuts Terns deal price after TERN-701 data review, while maintaining interest amid competition and CML treatment comparisons.
04-08 02:28
What's Going On With Merck Stock Tuesday?
Merck begins tender offer for Terns at $53 per share as part of its planned acquisition announced in March 2026.
04-08 00:46
Merck Locks Infinimmune Alliance To Chase Next-Gen Antibody Drugs
Infinimmune, Merck ink deal to develop human-derived antibodies using the Anthrobody platform. See the full agreement details.
04-01 21:26
美股大行评级 | 存储分歧大！花旗大砍17%将美光目标价从510降至425美元；Bernstein上调希捷科技目标价从500升至620美元
今日重点评级关注：Maxim Group：上调Theriva Biologics评级至"买入"，目标价1美元；HC Wainwright & Co.：维持Bicara Therapeutics"买入"评级，目标价从40美元升至42美元
04-01 16:34
美股大行评级 | 潜在涨幅172.14%！Alumis获Oppenheimer上调目标价至55美元；摩根大通首予希捷科技"超配"评级，目标价525美元
今日重点评级关注：Oppenheimer：维持Alumis"跑赢大市"评级，目标价从50美元升至55美元；美银证券：维持Rocket Pharmaceuticals"买入"评级，目标价从8美元升至9美元
03-31 16:30
财报速睇 | Terns Pharmaceuticals, Inc. 2025财年年度营收0.00亿美元，同比增长0.0%；归母净利润亏损0.96亿美元，同比亏损扩大7.9%
华盛资讯3月31日讯，Terns Pharmaceuticals, Inc.公布2025财年年度业绩，公司年度营收0.00亿美元，同比增长0.0%，归母净利润亏损0.96亿美元，同比亏损扩大7.9%。
03-31 06:47
